Kallidin- and bradykinin-degrading pathways in human heart. Degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase

Circulation

Volumn 99, Issue 15, 1999, Pages 1984-1990

  Kokkonen, Jorma O ^a   Kuoppala, Antti ^a   Saarinen, Juhani ^a   Lindstedt, Ken A ^a   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Bradykinin; Growth substances; Heart failure; Peptides; Remodeling

Indexed keywords

BRADYKININ; KALLIDIN; MEMBRANE METALLOENDOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART DILATATION; HEART FAILURE; HEART HEMODYNAMICS; HEART PROTECTION; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; KALLIKREIN KININ SYSTEM; PRIORITY JOURNAL;

EID: 0033586667     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.15.1984     Document Type: Article

References (31)

1. Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol. 1996;77:8C-16C.
2. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995;91: 2043-2048.
3. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J. Clin Invest. 1997;99:1926-1935.
4. Wollert KC, Studer R, Doefer K, Schieffer E, Holubarsch C, Just H, Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation. 1997;95:1910-1917.
5. Dorer FE, Kahn JR, Lentz KE, Levine M, Skeggs LT. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ Res. 1974;24: 824-827.
6. Campbell DJ, Kladis A, Duncan AM. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 1993;21:155-165.
7. Baumgarten CR, Linz W, Kunkel G, Scholkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol. 1993;108:293-295.
8. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 1997;81:848-856.
9. Hecker M, Blaukat A, Bara AT, Müller-Esterl W, Busse R. ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br J Pharmacol. 1997;121:1475-1481.
10. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994; 23:439-449.
11. Urata H, Healy B, Stewart RW, Bumbus FM, Husain A. Angiotensin II-forming pathways in normal and failing hearts. Circ Res. 1990;66: 883-890.
12. Hatzoglou A, Prekezes J, Tsami M, Castanas E. Protein measurement of paniculate and solubilized ovine liver membranes. Ann Clin Biochem. 1992;29:659-662.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
14. Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid: inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation. 1997;95:1455-1463.
15. Orawski AT, Susz JP, Simmons WH. Metabolism of bradykinin by multiple coexisting membrane-bound peptidases in lung: techniques for investigating the role of each peptide using specific inhibitors. Adv Exp Med Biol. 1989;247B:355-364.
16. Palmieri FE, Bausback HH, Ward PE. Metabolism of vasoactive peptides by vascular endothelium and smooth muscle aminopeptidase M. Biochem Pharmacol. 1989;38:173-180.
17. Sybertz EJ, Chiu PJS, Vemulapalli S, Pitts B, Foster CJ, Watkins RW, Barnett A, Haslanger MF. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther. 1989;250:624-631.
18. Fujita K, Matsumura Y, Kita S, Hisaki K, Takaoka M, Morimoto S. Phosphoramidon-sensitive conversion of big endothelin-1 and degradation of endothelin-1 in rat kidney. Hypertension. 1994;24:227-233.
19. Skidgel RA, Engelbrecht S, Johnson AR, Erdös EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides. 1984;5:769-776.
20. Nolly HL, Saed G, Scicli G, Carretero OA, Scicli AG. The kallikrein-kinin system in cardiac tissue. In: Recent Progress on Kinins. Basel, Switzerland: Birkhäuser Verlag; 1992:62-72.
21. Proud D, Subauste MC, Ward PE. Glucocorticoids do not alter peptidase expression on a human bronchial epithelial cell line. Am J Resp Cell Mol Biol. 1994;11:57-65.
22. Ikemoto F, Song G-B, Tominaga M, Yamamoto K. Endogenous inhibitor of angiotensin-converting enzyme in the rat heart. Biochem Biophys Res Commun. 1989;159:1093-1099.
23. Stewart TA, Weare JA, Erdös EG. Purification and characterization of human converting enzyme (kininase II). Peptides. 1981;2:145-152.
24. Matsas R, Kenny AJ, Turner AJ. The metabolism of neuropeptides: the hydrolysis of peptides, including enkephalins, tachykinins, and their analogues, by endopeptidase 24.11. Biochem J. 1984;223:433-440.
25. Ura N, Carretero OA, Erdös EG. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 1987;32:507-513.
26. Dragovic T, Igic R, Erdös EG, Rabito SF. Metabolism of bradykinin by peptidases in the lung. Am Rev Resp Dis. 1993;147:1491-1496.
27. Schilero GJ, Almenoff P, Cardozo C, Lesser M. Effects of peptidase inhibitors on bradykinin-induced bronchoconstriction in the rat. Peptides. 1994;15:1445-1449.
28. Vaghy PL, Russell JS, Lantry LE, Stephens RE, Ward PE. Angiotensin and bradykinin metabolism by peptidases identified in cultured human skeletal muscle myocytes and fibroblasts. Peptides. 1995;16:1367-1373.
29. Piedimonte G, Nadel JA, Long CS, Hoffman JIE. Neutral endopeptidase in the heart: neutral endopeptidase inhibition prevents isoproterenolinduced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ Res. 1994;75:770-779.
30. Gafford JT, Skidgel RA, Erdös EG, Hersh LB. Human kidney "enkephalinase," a neutral metalloendopeptidase that cleaves active peptides. Biochemistry. 1983;22:3265-3271.
31. Llorens-Cortes C, Huang H, Vicart P, Gase J-M, Paulin D, Corvol P. Identification and characterization of neutral endopeptidase in endothelial cells from venous and arterial origins. J Biol Chem. 1992;267: 14012-14018.